Trial Profile
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 May 2023
Price :
$35
*
At a glance
- Drugs SNP 610 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors Sinew Pharma
- 28 Apr 2023 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.
- 28 Apr 2023 Planned primary completion date changed from 30 Dec 2023 to 30 Dec 2024.
- 28 Apr 2023 Planned initiation date changed from 1 Dec 2022 to 1 Mar 2024.